These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9315428)

  • 21. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
    Klose G
    Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
    Marschner IC; Colquhoun D; Simes RJ; Glasziou P; Harris P; Singh BB; Friedlander D; White H; Thompson P; Tonkin A;
    J Am Coll Cardiol; 2001 Jul; 38(1):56-63. PubMed ID: 11451296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
    Tonkin AM
    Am J Cardiol; 1995 Sep; 76(9):107C-112C. PubMed ID: 7572678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
    Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
    Den Hartog FR; Van Kalmthout PM; Van Loenhout TT; Schaafsma HJ; Rila H; Verheugt FW
    Int J Clin Pract; 2001 Jun; 55(5):300-4. PubMed ID: 11452676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
    Morris S
    Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
    Shepherd J
    Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
    Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
    Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
    Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
    J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What is the role of pravastatin in the secondary prevention of coronary disease?].
    Mahé I
    Presse Med; 1999 Apr; 28(13):691. PubMed ID: 10228480
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pravastatin therapy and the risk of stroke.
    White HD; Simes RJ; Anderson NE; Hankey GJ; Watson JD; Hunt D; Colquhoun DM; Glasziou P; MacMahon S; Kirby AC; West MJ; Tonkin AM
    N Engl J Med; 2000 Aug; 343(5):317-26. PubMed ID: 10922421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
    White HD; Tonkin A; Simes J; Stewart R; Mann K; Thompson P; Colquhoun D; West M; Nestel P; Sullivan D; Keech AC; Hunt D; Blankenberg S;
    J Am Coll Cardiol; 2014 Feb; 63(4):345-54. PubMed ID: 24140630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.